On April 28, 2022 Orion reported interim report (Presentation, Orion , APR 28, 2022, View Source [SID1234613200]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 28, 2022 Corcept Therapeutics Incorporated (NASDAQ: CORT) reported it will report first quarter financial results and provide a corporate update on May 5, 2022 (Press release, Corcept Therapeutics, APR 28, 2022, https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-announce-first-quarter-financial-results-7 [SID1234613198]). The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information
To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time.

Click to Join Meeting

Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call. The passcode will be 6942208.

A replay will be available through May 12, 2022, at 1-855-859-2056 from the United States and 1-404-537-3406 internationally. The passcode will be 6942208. You may also access a replay on the Investors / Past Events tab of www.corcept.com

On April 28, 2022 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, reported that it will present its first quarter 2022 financial results and operational highlights in a conference call on May 5, 2022, at 8 a.m. ET (Press release, Intellia Therapeutics, APR 28, 2022, View Source [SID1234613197]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To join the call:

U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
Please visit this link for a simultaneous live webcast of the call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on May 5, 2022, at 12 p.m. ET.

On April 26, 2022 Argonaut Therapeutics, a leading developer of novel cancer agents, reported a company showcase presentation at the BioTrinity 2022 event, an international conference focused on bio-partnering and investment (Press release, Argonaut Therapeutics, APR 28, 2022, View Source [SID1234613196]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation to an audience of key industry investors and experts highlighted Argonaut Therapeutics vision to become a leading company in delivering innovative treatments to treat deadly cancers and provided an overview of the company’s proprietary assets and platforms, with an expanded focus on novel drug targets discovered in cancer relevant pathways.

About BioTrinity

BioTrinity is an established, must-attend London conference, that catalyses growth and supports in- person re-engagement across the life sciences industry. The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.

Professor Nick La Thangue, Founder and Chief Scientific Officer of Argonaut Therapeutics, and Professor of Cancer Biology in the Department of Oncology at Oxford University, commented:

"Arginine methylation is an extremely important process under aberrant control in many different cancers and drugs targeting arginine methylation will find clinical utility in diverse indications. We are delighted to have been invited to present in the oncology session at the BioTrinity 2022 event and share details on Argonaut’s novel and exciting asset pipeline".

Listen to Argonaut’s BioTrinity 2022 presentation here

On April 28, 2022 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, reported that the closing date of the previously announced acquisition of Héra SAS ("HRA" or "HRA Pharma") is expected to occur on April 29, 2022, subject to the satisfaction or waiver of the remaining closing conditions set forth in the securities sale agreement (Press release, Perrigo Company, APR 28, 2022, View Source [SID1234613195]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!